- Home
- CHI vs AVXL Comparison
CHI vs AVXL Comparison
Compare CHI & AVXL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CHI
- AVXL
- Stock Information
- Founded
- CHI 2002
- AVXL 2004
- Country
- CHI United States
- AVXL United States
- Employees
- CHI N/A
- AVXL N/A
- Industry
- CHI Investment Managers
- AVXL Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- CHI Finance
- AVXL Health Care
- Exchange
- CHI Nasdaq
- AVXL Nasdaq
- Market Cap
- CHI 853.5M
- AVXL 956.7M
- IPO Year
- CHI N/A
- AVXL N/A
- Fundamental
- Price
- CHI $11.29
- AVXL $8.03
- Analyst Decision
- CHI
- AVXL Strong Buy
- Analyst Count
- CHI 0
- AVXL 3
- Target Price
- CHI N/A
- AVXL $44.00
- AVG Volume (30 Days)
- CHI 186.2K
- AVXL 1.3M
- Earning Date
- CHI 01-01-0001
- AVXL 08-12-2025
- Dividend Yield
- CHI 9.90%
- AVXL N/A
- EPS Growth
- CHI N/A
- AVXL N/A
- EPS
- CHI N/A
- AVXL N/A
- Revenue
- CHI N/A
- AVXL N/A
- Revenue This Year
- CHI N/A
- AVXL N/A
- Revenue Next Year
- CHI N/A
- AVXL N/A
- P/E Ratio
- CHI N/A
- AVXL N/A
- Revenue Growth
- CHI N/A
- AVXL N/A
- 52 Week Low
- CHI $9.70
- AVXL $5.62
- 52 Week High
- CHI $11.61
- AVXL $14.44
- Technical
- Relative Strength Index (RSI)
- CHI 60.47
- AVXL 34.32
- Support Level
- CHI $10.86
- AVXL $7.88
- Resistance Level
- CHI $11.50
- AVXL $9.50
- Average True Range (ATR)
- CHI 0.16
- AVXL 0.50
- MACD
- CHI 0.01
- AVXL -0.12
- Stochastic Oscillator
- CHI 69.12
- AVXL 9.26
About CHI Calamos Convertible Opportunities and Income Fund
CALAMOS CONVERTIBLE OPPORTUNITIES & INCOME FUND operates as a closed-end management investment company. Its investment objective is to provide total return through a combination of capital appreciation and current income. The Fund invests in convertible securities and high-yield securities.
About AVXL Anavex Life Sciences Corp.
Anavex Life Sciences Corp is a clinical-stage biopharmaceutical company engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system diseases with high unmet need. It analyzes genomic data from clinical studies to identify biomarkers, which are further used in the analysis of clinical trials. The company's focus is on developing treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders. Its various therapeutic candidates in different stages of development include Anavex 2-73 (Blacamesine), Anavex 3-71 (AF710B), Anavex 1-41, and Anavex 1066.